Mice that received rituximab-armed iNK-CD64/16A cells showed a significantly lower tumor burden (Figures 6B, C), which was associated with increased survival (Figure 6D), compared to mice administered Raji cells and unarmed iNK-CD64/16A cells. This evidence concerns the gene FCGR1A and neoplasm.